Urologic Oncology: Seminars and Original Investigations This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Robotic-assisted vs. open radical prostatectomy: A machine learning framework for intelligent analysis of patient-reported outcomes from online cancer support groups
Robot-assisted radical prostatectomy (RARP) is being increasingly utilised in treatment of prostate cancer (CaP). In addition to the minimally invasive nature, some of the reported perioperative advantages of RARP include lower surgical margin rate for intermediate-risk disease and high-risk disease, lower blood loss, lower risk of blood transfusions, and shorter hospital stays [1 –7]. However, quality of life (QOL) in the longer term is more contentious. Clinical trials conducted in high volume centres depend on willing participants filling out questionnaires on a long-term basis in a ‘trial setting’ and thereby lik...
Source: Urologic Oncology: Seminars and Original Investigations - September 17, 2018 Category: Urology & Nephrology Authors: Weranja Ranasinghe, Daswin de Silva, Tharindu Bandaragoda, Achini Adikari, Damminda Alahakoon, Raj Persad, Nathan Lawrentschuk, Damien Bolton Tags: Original article Source Type: research

Abbreviated CT protocol for postoperative surveillance of renal cancer
The current protocols for surveillance following surgery for localized renal cell carcinoma (RCC) stratify patients according to risk groups [1 –4]. Periodic computed tomography (CT) scans of the chest and abdomen are recommended according to risk groups with some variations between the different guidelines. Given that CT is a very sensitive tool for detection of early and potentially curable metastasis and local recurrence [5–8], over the evolution of successive guideline recommendations more and more CT studies have been added to the protocols [1]. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - September 15, 2018 Category: Urology & Nephrology Authors: Ofer N. Gofrit, Igal Rabinovich, Vladimir Yutkin, Dov Pode, Mordechai Duvdevani, Ezekiel H. Landau, Guy Hidas, S. Nahum Goldberg Tags: Original article Source Type: research

Risk prediction models for cancer-specific survival following cytoreductive nephrectomy in the contemporary era
Level 1 evidence supports a survival benefit to cytoreductive nephrectomy (CN) followed by cytokine therapy in patients with metastatic renal cell carcinoma (mRCC) [1 –3]. Although comparable randomized data do not exist for patients treated with targeted therapies, several retrospective studies suggest a similar survival benefit for CN [4–6]. However, it is unclear whether selection criteria and treatment sequencing paradigms developed during the immunothera py era are applicable to patients treated within the contemporary targeted therapy era. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - September 15, 2018 Category: Urology & Nephrology Authors: Timothy D. Lyon, Boris Gershman, Paras H. Shah, R. Houston Thompson, Stephen A. Boorjian, Christine M. Lohse, Brian A. Costello, John C. Cheville, Bradley C. Leibovich Tags: Original Article Source Type: research

Association between renal mass biopsy and upstaging to perinephric fat involvement in a contemporary cohort of patients with clinical T1a renal cell carcinoma
The appropriate management of small renal masses has been debated extensively. Numerous management options, including extirpative surgery, ablative techniques, and active surveillance are available for these tumors [1]. From a population standpoint, the increased detection and treatment, without a resultant survival benefit, raises a concern for overtreatment of these tumors [2]. Currently, tumor size, growth rate, and histopathologic evaluation of tumor biopsy samples (in selected patients) are used for risk stratification and decision making in small renal tumors [3,4]. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - September 15, 2018 Category: Urology & Nephrology Authors: Amirali Salmasi, Izak Faiena, Andrew T. Lenis, Aydin Pooli, David C. Johnson, Alexandra Drakaki, Kiran Gollapudi, Jeremy Blumberg, Allan J. Pantuck, Karim Chamie Tags: Original article Source Type: research

Reported rates of clostridium difficile following radical cystectomy in national datasets compared to individual institutions
The Centers for Disease Control and Prevention (CDC) estimates that there were approximately 453,000 cases and 30,000 deaths caused by Clostridium difficile infection (CDI) in 2011, making it the most common healthcare acquired infection [1]. Rates of CDI in US hospitals range from 3.8 to 9.5 cases per 10,000 patient days [2]. Clostridium difficile is a gram-positive anaerobic organism that typically colonizes the gut asymptomatically. Symptoms may manifest if the microenvironment is disrupted, which is usually due to antibiotic exposure, but may also be due to intestinal surgery. (Source: Urologic Oncology: Seminars and O...
Source: Urologic Oncology: Seminars and Original Investigations - September 15, 2018 Category: Urology & Nephrology Authors: Reece Miller, Jonathan E. Heinlen Tags: Original article Source Type: research

tRNA-halves are prognostic biomarkers for patients with prostate cancer
Prostate cancer (CaP) is the second most common malignancy in men [1]. The diagnosis is based on digital rectal examination, prostate-specific antigen (PSA), prostate biopsy, and imaging modalities. Despite the efforts for accurate diagnosis, a high percentage of men diagnosed with CaP is overtreated with radical prostatectomy or radiotherapy [2,3]. On the other hand, a subset of patients with aggressive carcinoma faces the risk of CaP progression despite of treatment. Therefore, a biomarker allowing the identification of aggressive and indolent disease is required in order to improve the management of patients with CaP. (...
Source: Urologic Oncology: Seminars and Original Investigations - September 9, 2018 Category: Urology & Nephrology Authors: Chenming Zhao, Yuri Tolkach, Doris Schmidt, Michael Muders, Glen Kristiansen, Stefan C. M üller, Jörg Ellinger Tags: Original article Source Type: research

Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting
Prostate cancer currently represents 19% of all new cancer diagnoses in American men [1]. Despite response rates exceeding 80% with androgen deprivation therapy, effects of hormonal manipulation are temporary, and most patients progress to metastatic castration-resistant prostate cancer (mCRCaP) within a median of 3 years of diagnosis [2]. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - September 7, 2018 Category: Urology & Nephrology Authors: William K. Oh, Wendy Y. Cheng, Raymond Miao, Francis Vekeman, Marjolaine Gauthier-Loiselle, Mei Sheng Duh, Edward Drea, Ted P. Szatrowski Tags: Original article Source Type: research

miR-301a expression: Diagnostic and prognostic marker for prostate cancer
This study establishes the role of microRNA 301a (miR-301a) as a supplemental biomarker that can distinguish between patients with benign prostate hyperplasia and clinically significant CaP. We evaluate the ability of miR-301a to predict the adverse pathology of CaP. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - September 5, 2018 Category: Urology & Nephrology Authors: Venkatesh Kolluru, Balaji Chandrasekaran, Ashish Tyagi, Adnan Dervishi, Murali Ankem, Xiaofang Yan, Kong Maiying, Houda Alatassi, Saad P. Shaheen, Ahmed Haddad, Chendil Damodaran, Jamie C. Messer, Angelena Edwards Tags: Original Article Source Type: research

The Whitmore aphorism
Willet F. Whitmore Jr. served as the chief of urology at Memorial Sloan-Kettering Cancer Center from 1951 to 1984. In his New York Times obituary, he is aptly referred to as, "the dean of urologic oncology ” [1]. He had a major impact on the practice of urologic oncology, particularly prostate cancer. His influence on the field extended beyond his own lifetime, as he trained many of the next generation of urologic oncology leaders. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - September 4, 2018 Category: Urology & Nephrology Authors: Kevin R. Loughlin Tags: Review Article Source Type: research

Physician attitudes about genetic testing for localized prostate cancer: A national survey of radiation oncologists and urologists
Prostate cancer is a highly prevalent male malignancy with approximately 180,000 diagnosed and 30,000 dying each year in the United States [1]. Due to the indolent natural history of prostate cancer, greater emphasis is now placed on shared decision-making and active surveillance to address concerns about overtreatment [2]. Effective treatment decision-making for localized prostate cancer therefore requires accurate predictive tools to best quantify clinical aggressiveness and risk of cancer-related morbidity and mortality at the time of diagnosis [3,4]. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - September 3, 2018 Category: Urology & Nephrology Authors: Simon P. Kim, Neal J. Meropol, Cary P. Gross, Jon C. Tilburt, Badrinath Konety, James B. Yu, Robert Abouassaly, Christopher J. Weight, Stephen B. Williams, Nilay D. Shah Tags: Original article Source Type: research

Receptor activator of NF- κB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma
According to histological criteria, renal cell carcinoma (RCC) can be classified into 3 major subtypes: clear cell renal cell carcinoma (ccRCC), papillary RCC, and chromophobe RCC [1]. The most frequent subtype is ccRCC, accounting for approximately 75% of all RCC cases [1]. Metastatic renal cell carcinoma (mRCC) is a chemo- and irradiation-resistant tumor with a historical median overall survival (OS) of RCC patients of approximately 10 months [2]. Despite the recent success of new treatment strategies with targeted therapies and specific immunotherapies in the treatment of mRCC, many tumors are resistant to current stand...
Source: Urologic Oncology: Seminars and Original Investigations - August 28, 2018 Category: Urology & Nephrology Authors: Andr é Steven, Sandra Leisz, Sebastian Fussek, Behdokht Nowroozizadeh, Jiaoti Huang, Daniel Branstetter, William C. Dougall, Martin Burchardt, Arie S. Belldegrun, Barbara Seliger, Allan Pantuck, Nils Kroeger Tags: Original article Source Type: research

Primary care perspective and implementation of a multidisciplinary, institutional prostate cancer screening algorithm embedded in the electronic health record
Recognizing historical widespread national prostate-specific antigen (PSA) screening programs, subsequent early prostate cancer (CaP) detection and resulting stage migration, the CaP-specific mortality rate decreased by 40% during the past three decades [1,2]. Despite this great achievement, there are still many controversies regarding the benefits/harms of CaP screening. While the United States Preventive Services Task Force (USPSTF) recently changed their recommendation against routine screening of all men at all ages (Grade D) to individualized patient –physician decision-making for men aged 55 to 69 years (Grade C) [...
Source: Urologic Oncology: Seminars and Original Investigations - August 28, 2018 Category: Urology & Nephrology Authors: Alireza Aminsharifi, Ariel Schulman, John Anderson, Laura Fish, Kevin Oeffinger, Kevin Shah, Christina Sze, Kae J. Tay, Efrat Tsivian, Thomas J. Polascik Tags: Original article Source Type: research

A comparison of perinephric fat surface area and Mayo Adhesive Probability score in predicting malignancy in T1 renal masses
Recent studies have proposed that nearby fat deposits may have metabolic influence on kidney cancer pathobiology. Both fat quantity and quality may play unique roles in this complex relationship. As such, we investigated whether perinephric fat surface area (PFA), a quantitative measure of fat, or Mayo Adhesive Probability (MAP) score, a qualitative measure, were predictive of malignant pathology or Fuhrman grade in small renal masses. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - August 27, 2018 Category: Urology & Nephrology Authors: Ari Bernstein, Ethan B. Fram, Alexander Sankin, Evan Kovac, Abhishek Srivastava, Joseph DiVito, Joshua M. Stern Tags: Original article Source Type: research

Nongenitourinary complications associated with robot-assisted laparoscopic and radical retropubic prostatectomy: A single institution assessment of 1,100 patients over 11 years
The debate regarding the advantages and disadvantages of robot-assisted laparoscopic prostatectomy (RALP) and open radical retropubic prostatectomy (RRP) has largely been resolved. Currently, most evidence purporting the superiority of RALP has come from observational cohort studies and meta-analyses [1 –5]. To date, no extensive randomized controlled trial comparing the two techniques has been performed [6,7]. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - August 25, 2018 Category: Urology & Nephrology Authors: Nathan A. Brooks, Riley S. Boland, Michael E. Strigenz, Sarah L. Bell, James A. Brown Tags: Original article Source Type: research

Lymph node yield as a predictor of overall survival following inguinal lymphadenectomy for penile cancer
Penile cancer is rare in the United States (US) with an incidence of 0.58/100,000 [1]. The majority of cases are squamous cell carcinoma. Management of penile squamous cell carcinoma (pSCC) is based on local invasiveness of the tumor, tumor grade, and staging of regional (inguinal and pelvic) lymph nodes (LNs) [2]. Involvement of the regional LNs is an adverse pathological finding and has been demonstrated to influence cancer-specific survival (CSS) and overall survival (OS) [3]. Inguinal lymphadenectomy (ILND) is, therefore, an important part of the treatment algorithm for clinically node positive disease (cN+) [4]. (Sour...
Source: Urologic Oncology: Seminars and Original Investigations - August 22, 2018 Category: Urology & Nephrology Authors: Nachiketh Soodana-Prakash, Tulay Koru-Sengul, Feng Miao, Diana M. Lopategui, Luis F. Savio, Kevin J. Moore, Taylor A. Johnson, Mahmoud Alameddine, Marcelo Panizzutti Barboza, Dipen J. Parekh, Sanoj Punnen, Mark L. Gonzalgo, Chad R. Ritch Tags: Original article Source Type: research